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PROSPECTIVE OBSERVATIONAL STUDY OF PATIENT
REPORTED OUTCOMES FOR AZITHROMYCIN VS. USUAL
CARE IN THE TREATMENT OF ACUTE BACTERIAL
EXACERBATIONS OF CHRONIC BRONCHITIS
Milstone AP1, Feurer I1, Harnett J2, Luke DR2
1Vanderbilt University Medical Center, Nashville,TN, USA; 2Pﬁzer Inc,
New York, NY, USA
OBJECTIVE: A three-day azithromycin course (500mg/day) was
recently introduced in the US. Our study evaluated patient-
reported outcomes and resource utilization following a three-day
azithromycin course in the treatment of acute exacerbations of
chronic bronchitis (AECB). METHODS: This prospective, mul-
ticenter study evaluated outpatients with AECB who received
either three-day azithromycin (AZM) or 5–14 day courses of
other antibiotics (usual care group; UCG) as directed by the
physician. A total of 128 patients (57 AZM, 71 UCG) completed
two heath-related quality of life instruments, the St. George’s
Respiratory Questionnaire (SGRQ) and Short Form 36 (SF-36),
at baseline, day 14, and end of study (days 24–28), and a diary
for the ﬁrst 14 days after start of antibiotic therapy. RESULTS:
The only difference between treatment groups was a higher per-
centage of diabetics in the UCG compared with the AZM (17%
vs. 2%; P = 0.02). Both groups reported similar improvement in
signs and symptoms, absenteeism, concomitant respiratory med-
ication use, resource utilization, compliance, and treatment sat-
isfaction as reported in the 14-day diary. AZM had signiﬁcant
improvement in all SGRQ measures and in the SF-36 mental and
physical summary components over the course of the study (P <
0.01). The UCG reported signiﬁcant improvement in all SGRQ
measures and in the SF-36 physical component (P < 0.01), but
not in the SF-36 mental component scores (P = 0.10). In total,
78% AZM and 56% UCG had a > four-point improvement on
the SGRQ total score at EOS; however, this difference was not
statistically signiﬁcant in multivariate analysis (P = 0.06). A sig-
niﬁcantly greater activity scale improvement was found for the
AZM group compared with the UCG (P = 0.008). CONCLU-
SIONS: The three-day course of azithromycin 500mg/day had
signiﬁcant impact on patient reported outcomes, as measured by
the SGRQ, SF-36, and patient diary. Further, this regimen pro-
duced a greater improvement on the SGRQ activity scale com-
pared with UCG.
INFECTION—HIV
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THE COST-EFFECTIVENESS OF PREVENTING MOTHER-TO-
CHILD TRANSMISSION OF HIV IN CHINA
Zhang H, Zaric GS
University of Western Ontario, London, ON, Canada
OBJECTIVES: Several interventions for reducing mother-to-
child transmission of HIV (MTCT) have been implemented inter-
nationally. In some cities in China, HIV testing is required for
all pregnant women and funding for MTCT prevention is paid
by the government. However, a standard practice has not been
determined. We evaluate the cost-effectiveness of ﬁve interven-
tions for preventing MTCT of HIV in China. METHODS: 
We developed a decision analytic model to compare the costs,
health beneﬁts and cost-effectiveness of the ﬁve alternatives. We
evaluated avoiding breastfeeding only, single-dose nevirapine,
short-course zidovudine, long-course zidovudine, or long-course
HAART. In the base case, we considered national program
implementation in which approximately 15,000,000 women
would receive HIV tests annually. We constructed additional 
scenarios to investigate regional differences in HIV prevalence
cohort size. All costs were expressed in 2003 USD. RESULTS:
HAART is the most cost-effective of the ﬁve interventions if
implemented nation-wide. If HAART was offered to all women
following a positive HIV test result, it would prevent 1,890 new
infections annually and lead to a gain of 39,900 life years (LY).
The total cost is $209,000,000, or $5,200/LY gained. HAART
becomes more cost-effective as the baseline prevalence increases.
In extensive sensitivity analysis, HAART remained the most cost-
effective intervention. If avoiding breastfeeding is already the
status quo, then single-dose nevirapine is the most cost-effective
alternative and is cost saving. CONCLUSIONS: We are not
aware of a cost-effectiveness threshold that is appropriate for
China. However, HAART is the most cost-effective alternative
in a number of different scenarios. In spite of being the most
cost-effective option, the total drug cost of implementing
HAART nationally may necessitate consideration of other 
alternatives.
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COST OF THERAPY FOR ARV NAIVE HIV-INFECTED
PATIENTS: FOSAMPRENAVIR / RITONAVIR 
VERSUS NELFINAVIR
Lee WC1, Hoffmann M1, Stephens J1,Williams K2, Liu LZ2,
Pashos CL3
1Abt Associates, Bethesda, MD, USA; 2Pﬁzer Global Pharmaceuticals,
New York, NY, USA; 3Abt Associates, Lexington, MA, USA
The recent SOLO clinical trial demonstrated that the efﬁcacy 
at 48 weeks of HAART regimens containing fosamprenavir/
ritonavir vs. nelﬁnavir in treatment-naïve patients was similar.
However, relative cost comparisons of the two regimens have not
been evaluated in light of the 400% price increase of ritonavir.
OBJECTIVES: A cost comparison analysis was conducted 
of HAART regimens fosamprenavir/ritonavir vs. nelﬁnavir.
METHODS: Clinical efﬁcacy and dosing parameters were
extracted from the SOLO trial and package inserts. Although
recommendations dictate twice daily dosing regimens for pro-
tease inhibitors, the baseline assumption for treatment-naïve
patients was the recommended 1400/200mg once daily dosing
regimen. The efﬁcacy of nelﬁnavir 250mg and 650mg was
assumed to be identical. Sensitivity analysis was conducted on
cost of therapy and cost savings for different scenarios of average
wholesale price (AWP), discounts from the AWP, and number of
tablets per day. Daily, monthly, and 48-week costs of nelﬁnavir
versus ritonavir-boosted fosamprenavir were compared.
RESULTS: Due to the price change in ritonavir, the drug acqui-
sition cost per day of fosamprenavir boosted with ritonavir
increased 73% from $23.48 to $40.71. The nelﬁnavir 625mg
twice daily dosing regimen resulted in monthly cost savings of
$502 and a 48-week cost-reduction of $5545 (41%) compared
to fosamprenavir/ritonavir 1400/200mg once daily regimen. A
discount of approximately 75% on the ritonavir AWP would
make the drug acquisition cost of fosamprenavir boosted with
ritonavir equal to that of nelﬁnavir. CONCLUSION: The price
increase of ritonavir signiﬁcantly affects drug acquisition cost 
for patients taking fosamprenavir and other boosted protease
inhibitors. Without compromising clinical efﬁcacy, nelﬁnavir
provides a cost-saving alternative for treatment-naïve HIV-
infected patients compared to ritonavir-boosted fosamprenavir.
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Zilberberg M1, Mody SH2,Ambegaonkar BM3
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OBJECTIVES: To understand the current extent of anemia in
HIV/AIDS patients and its impact on health-related quality of
life (HRQL). METHODS: HIV/AIDS patients >18 years of age
were recruited from STD/HIV clinics across the US throughout
2003 to complete self-administered questionnaires. Clinical
status was assessed with questions on medical history and HIV
disease and treatment, while HRQL was quantiﬁed using the SF-
8. RESULTS: In total, 2044 patients were recruited; 498 (24%)
reported that they experienced anemia (as indicated by a health
care provider) as a side effect of medication within the previous
month. Although anemic and non-anemic individuals were
similar in age, gender, HIV viral load, and use of AZT, NRTI
and NNRTI treatment, anemic patients were more likely to be
non-Caucasian, have a lower CD4 count, and more likely to be
on PIs. Similarly, anemic patients were signiﬁcantly more likely
to have anxiety, depression, and cardiovascular comorbidities 
(p < 0.0001). Further, anemic patients had signiﬁcantly lower
scores vs. non-anemic patients on the mental and physical com-
ponent summary scores of the SF-8 (mental: 38.2 + 11.6 anemic
vs. 42.9 + 11.9 non-anemic p < 0.0001; physical: 40.1 + 10.0
anemic vs. 45.5 + 10.4 non-anemic p < 0.0001). There was a sig-
niﬁcantly higher prevalence of great difﬁculty or inability to
perform daily work among the anemic patients (33% anemic vs.
19% non-anemic, p < 0.0001). In a multivariate logistic regres-
sion model controlling for relevant demographic, disease and
treatment characteristics, anemic patients experienced signiﬁ-
cantly lower levels of mental (-4.1 SF-8 MCS score, p < 0.001)
and physical (-4.9 SF-8 PCS score, p < 0.001) well-being than
non-anemic patients. CONCLUSION: Independent of AZT use,
anemia is prevalent in the HIV/AIDS population in the HAART
era. Controlling for relevant confounders, anemia is indepen-
dently associated with a diminished HRQL.
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USE OF THE SYMPTOMS DISTRESS MODULE IN AN
INTERNATIONAL STUDY
Mear I1, D’Uva F1,Wu AW2, Mollon P3
1Mapi Research Institute, Lyon, Rhône, France; 2Johns Hopkins
Bloomberg School of Public Health, Baltimore, MD, USA; 3Pﬁzer, Kent,
Sandwich, UK
OBJECTIVES: Prior to use in an international study involving
HIV patients, the original 20-item Symptoms Distress Module
(SDM), underwent linguistic validation in 25 languages. The
original scale was developed in US English by the Adult AIDS
Clinical Trials Group to assess the impact of common HIV-
related symptoms (either due to HIV disease or its treatments).
A rigorous methodology was required to ensure conceptual
equivalence and cultural relevance across different languages.
METHODS: The translation process was conducted by a spe-
cialist in each target country using the following standardized
methodology: 1) two forward translations by professional trans-
lators who were native speakers of the target language and ﬂuent
in English; 2) comparison and reconciliation of the translations
by the specialist in the target country and the translators; 3)
back-translation by a native English speaker; 4) comparison of
source and backward version; 5) review by a clinician; and 
6) comprehension test on ﬁve individuals with HIV/AIDS.
RESULTS: The translation process revealed two major chal-
lenges. First, for items which contain two different terms to
describe one single concept, some languages only have one word
that suitably conveys the concept. Second, the comprehension
tests revealed that in countries where people are less used to com-
pleting questionnaires, the instructions “The questionnaire . . .
should take no more than ﬁve minutes to complete” were per-
ceived as stressful. This required alternative wording. CON-
CLUSION: The 25 language versions of the SDM were estab-
lished according to a rigorous standardized translation method-
ology. The process aims to ensure conceptual equivalence across
language versions to facilitate international comparison and
pooling of data. The linguistic validation process as a whole sup-
ports the integration of international feedback on concepts and
wording during the development of questionnaires.
NEUROLOGICAL DISORDERS—Alzheimer’s Disease
PNL1
ASSESSMENT OF COMORBIDITY AND INCIDENCE RATE OF
ALZHEIMER’S DISEASE IN THE CALIFORNIA MEDICAID
(MEDI-CAL) PROGRAM
Yu YF1,Yu AP2, Lee LJ2, Nichol MB3
1HealthCore, Inc, Wilmington, DE, USA; 2University of Southern
California, Los Angeles, CA, USA; 3University of Southern California,
School of Pharmacy, Los Angeles, CA, USA
OBJECTIVES: First, to investigate comorbidities associated with
Alzheimer’s disease (AD) and second, to report eligibility and the
yearly trend of incidence rate of AD in Medi-Cal from 1995 to
2002. METHODS: A retrospective case-control study was con-
ducted using 20% sample of Medi-Cal administrative claims
data from 1995 to 2002. The cases were patients with a diag-
nosis of AD, and were 1 :10 matched to a cohort without AD
based on age and gender. Eligibility was measured by the number
of eligible months. Relative risk (RR) was calculated to estimate
the risk of AD patients developing a proﬁle of 24 common
comorbidities set forth by AHRQ. RESULTS: In total, 6,494
cases and 64,940 controls were identiﬁed. The average age was
84 and 69% were female. During the eight-year study period,
both groups had around 50 eligible months with no signiﬁcant
difference. Hispanics and other minorities (primarily Asians) had
lower risk of having AD (p < 0.0001). In addition to depression
(RR = 1.67) and psychoses (RR = 2.63), which are the known
comorbidities of AD, peripheral vascular disorder (RR = 1.49)
and other neurological disorders (RR = 1.82) were associated
with the AD diagnosis. Interestingly, AD patients had signiﬁ-
cantly lower risk for many other chronic diseases such as CHF
(RR = 0.82), valvular disease (RR = 0.85), hypertension (RR =
0.84), COPD (RR = 0.85), diabetes (RR = 0.85), renal failure
(RR = 0.86), peptic ulcer (RR = 0.86), cancer (RR = 0.69), and
rheumatoid arthritis (RR = 0.80). The yearly incidence rate for
AD slightly declined from 5.8 per 10,000 person-years in 1995
to 4.8 per 10,000 person-years in 2002. Average annual inci-
dence rate was 5.3 per 10,000 person-years. CONCLUSIONS:
The present study demonstrated that patients with AD had
increased risk of some diseases, yet were less likely to experience
many chronic disorders common to elderly patients.
PNL2
THE COST-EFFECTIVENESS OF DONEPEZIL AND
RIVASTIGMINE IN THE TREATMENT OF ALZHEIMER’S
DISEASE IN THAILAND PRIVATE HOSPITAL
Pattanaprateep O, Phongchareonsuk P, Chaikledkaew U
Mahidol University, Payathai, Bangkok,Thailand
OBJECTIVES: To evaluate the cost-effectiveness of donepezil 10
mg per day, rivastigmine 6–12mg per day (high dose), and
rivastigmine 1–4mg per day (low dose) compared with no treat-
ment in the management of mild to moderate Alzheimer’s
Disease in Thailand. METHODS: Using the decision tree analy-
sis, the cost-effectiveness model was developed to compare
donepezil, low dose-rivastigmine and high dose-rivastigmine
with no treatment in patients with mild to moderate Alzheimer’s
Disease. Direct medical costs (i.e., the costs of drugs) and direct
